Galderma to Acquire ZO Skin Health for $1.5 Billion
The Swiss firm agreed to purchase the medical-grade skincare company from private equity firm Blackstone and the founding Obagi family to expand its US portfolio.
Swiss pharmaceutical company Galderma Group AG has agreed to acquire ZO Skin Health for an enterprise value of $1.5 billion, according to Nasdaq Markets. The deal involves purchasing the medical-grade skincare company from its shareholders, which include the founding Obagi family and funds managed by Blackstone Tactical Opportunities, according to WSJ Markets. Business of Fashion notes the acquisition is intended to expand Galderma's US portfolio.
The acquisition is intended to expand Galderma's dermatological skincare portfolio and offering, according to Financial Post. The publication states that ZO Skin Health's premium daily multi-step regimens complement Alastin’s regenerative skincare portfolio, which focuses primarily on peri-procedure support.
Brief written by urgent.news from Business of Fashion, WSJ Markets, Nasdaq Markets, Financial Post — 4 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
